nodes	percent_of_prediction	percent_of_DWPC	metapath
Danazol—Progesterone—uterine cancer	0.285	1	CrCtD
Danazol—CCL2—uterine cancer	0.091	0.415	CbGaD
Danazol—PGR—uterine cancer	0.0554	0.253	CbGaD
Danazol—CYP19A1—uterine cancer	0.038	0.173	CbGaD
Danazol—PGR—Medroxyprogesterone Acetate—uterine cancer	0.0361	0.169	CbGbCtD
Danazol—ESR1—uterine cancer	0.035	0.159	CbGaD
Danazol—SHBG—Medroxyprogesterone Acetate—uterine cancer	0.0347	0.163	CbGbCtD
Danazol—AR—Medroxyprogesterone Acetate—uterine cancer	0.029	0.136	CbGbCtD
Danazol—ESR1—Medroxyprogesterone Acetate—uterine cancer	0.0251	0.118	CbGbCtD
Danazol—PGR—Progesterone—uterine cancer	0.0239	0.112	CbGbCtD
Danazol—SHBG—Progesterone—uterine cancer	0.023	0.108	CbGbCtD
Danazol—Trilostane—Progesterone—uterine cancer	0.0227	0.111	CrCrCtD
Danazol—AR—Progesterone—uterine cancer	0.0192	0.0901	CbGbCtD
Danazol—Stanozolol—Progesterone—uterine cancer	0.019	0.0927	CrCrCtD
Danazol—ESR1—Progesterone—uterine cancer	0.0166	0.0779	CbGbCtD
Danazol—Oxandrolone—Progesterone—uterine cancer	0.0154	0.0751	CrCrCtD
Danazol—Formestane—Progesterone—uterine cancer	0.0137	0.067	CrCrCtD
Danazol—Levonorgestrel—Progesterone—uterine cancer	0.0114	0.0554	CrCrCtD
Danazol—Cortisone acetate—Medroxyprogesterone Acetate—uterine cancer	0.0101	0.0495	CrCrCtD
Danazol—Norethindrone—Progesterone—uterine cancer	0.00913	0.0445	CrCrCtD
Danazol—Fluoxymesterone—Medroxyprogesterone Acetate—uterine cancer	0.00905	0.0441	CrCrCtD
Danazol—Cortisone acetate—Progesterone—uterine cancer	0.00884	0.0431	CrCrCtD
Danazol—Progesterone—Medroxyprogesterone Acetate—uterine cancer	0.00881	0.043	CrCrCtD
Danazol—Testosterone Propionate—Medroxyprogesterone Acetate—uterine cancer	0.00881	0.043	CrCrCtD
Danazol—Methyltestosterone—Medroxyprogesterone Acetate—uterine cancer	0.00859	0.0419	CrCrCtD
Danazol—Testolactone—Progesterone—uterine cancer	0.00858	0.0419	CrCrCtD
Danazol—Fluoxymesterone—Progesterone—uterine cancer	0.00789	0.0385	CrCrCtD
Danazol—Testosterone Propionate—Progesterone—uterine cancer	0.00768	0.0375	CrCrCtD
Danazol—Testosterone—Medroxyprogesterone Acetate—uterine cancer	0.00765	0.0373	CrCrCtD
Danazol—Methyltestosterone—Progesterone—uterine cancer	0.00749	0.0365	CrCrCtD
Danazol—Hydrocortisone—Medroxyprogesterone Acetate—uterine cancer	0.00719	0.0351	CrCrCtD
Danazol—Testosterone—Progesterone—uterine cancer	0.00667	0.0325	CrCrCtD
Danazol—Hydrocortisone—Progesterone—uterine cancer	0.00627	0.0306	CrCrCtD
Danazol—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.00257	0.0121	CbGbCtD
Danazol—PGR—corpus luteum—uterine cancer	0.00248	0.0974	CbGeAlD
Danazol—CYP19A1—corpus luteum—uterine cancer	0.00223	0.0876	CbGeAlD
Danazol—CYP3A4—Progesterone—uterine cancer	0.00171	0.008	CbGbCtD
Danazol—SHBG—semen—uterine cancer	0.00129	0.0506	CbGeAlD
Danazol—CCL2—artery—uterine cancer	0.00107	0.0422	CbGeAlD
Danazol—CYP19A1—semen—uterine cancer	0.00104	0.0411	CbGeAlD
Danazol—CCL2—exocrine gland—uterine cancer	0.000934	0.0368	CbGeAlD
Danazol—AR—semen—uterine cancer	0.000924	0.0363	CbGeAlD
Danazol—PGR—oviduct—uterine cancer	0.000851	0.0335	CbGeAlD
Danazol—CYP3A4—Etoposide—uterine cancer	0.000763	0.00358	CbGbCtD
Danazol—AR—oviduct—uterine cancer	0.000678	0.0267	CbGeAlD
Danazol—ESR1—oviduct—uterine cancer	0.000665	0.0262	CbGeAlD
Danazol—PGR—artery—uterine cancer	0.000563	0.0222	CbGeAlD
Danazol—CYP3A4—Doxorubicin—uterine cancer	0.000521	0.00244	CbGbCtD
Danazol—CCL2—myometrium—uterine cancer	0.000518	0.0204	CbGeAlD
Danazol—CCL2—Methylprednisolone—Medroxyprogesterone Acetate—uterine cancer	0.000444	0.447	CbGdCrCtD
Danazol—CCL2—epithelium—uterine cancer	0.000406	0.016	CbGeAlD
Danazol—CCL2—uterine cervix—uterine cancer	0.000403	0.0159	CbGeAlD
Danazol—CCL2—smooth muscle tissue—uterine cancer	0.000392	0.0154	CbGeAlD
Danazol—GNRHR—female reproductive system—uterine cancer	0.000387	0.0152	CbGeAlD
Danazol—CCL2—decidua—uterine cancer	0.000384	0.0151	CbGeAlD
Danazol—CCL2—renal system—uterine cancer	0.000377	0.0148	CbGeAlD
Danazol—CCL2—endometrium—uterine cancer	0.000364	0.0143	CbGeAlD
Danazol—CCL2—mammalian vulva—uterine cancer	0.000353	0.0139	CbGeAlD
Danazol—GNRHR—female gonad—uterine cancer	0.000352	0.0138	CbGeAlD
Danazol—CCL2—uterus—uterine cancer	0.000336	0.0132	CbGeAlD
Danazol—CCL2—female reproductive system—uterine cancer	0.000302	0.0119	CbGeAlD
Danazol—CCL2—Fluorometholone—Medroxyprogesterone Acetate—uterine cancer	0.000275	0.277	CbGdCrCtD
Danazol—CCL2—female gonad—uterine cancer	0.000275	0.0108	CbGeAlD
Danazol—CCL2—Flurandrenolide—Medroxyprogesterone Acetate—uterine cancer	0.000274	0.276	CbGdCrCtD
Danazol—CCL2—vagina—uterine cancer	0.000273	0.0107	CbGeAlD
Danazol—PGR—myometrium—uterine cancer	0.000272	0.0107	CbGeAlD
Danazol—AR—myometrium—uterine cancer	0.000217	0.00853	CbGeAlD
Danazol—PGR—epithelium—uterine cancer	0.000214	0.0084	CbGeAlD
Danazol—ESR1—myometrium—uterine cancer	0.000213	0.00837	CbGeAlD
Danazol—SHBG—endometrium—uterine cancer	0.000213	0.00836	CbGeAlD
Danazol—PGR—uterine cervix—uterine cancer	0.000212	0.00833	CbGeAlD
Danazol—PGR—smooth muscle tissue—uterine cancer	0.000206	0.0081	CbGeAlD
Danazol—PGR—decidua—uterine cancer	0.000202	0.00794	CbGeAlD
Danazol—SHBG—uterus—uterine cancer	0.000196	0.00771	CbGeAlD
Danazol—PGR—endometrium—uterine cancer	0.000192	0.00753	CbGeAlD
Danazol—CCL2—lymph node—uterine cancer	0.000177	0.00695	CbGeAlD
Danazol—PGR—uterus—uterine cancer	0.000177	0.00694	CbGeAlD
Danazol—SHBG—female reproductive system—uterine cancer	0.000176	0.00693	CbGeAlD
Danazol—CYP19A1—endometrium—uterine cancer	0.000172	0.00678	CbGeAlD
Danazol—AR—epithelium—uterine cancer	0.00017	0.00669	CbGeAlD
Danazol—AR—uterine cervix—uterine cancer	0.000169	0.00664	CbGeAlD
Danazol—ESR1—epithelium—uterine cancer	0.000167	0.00657	CbGeAlD
Danazol—ESR1—uterine cervix—uterine cancer	0.000166	0.00652	CbGeAlD
Danazol—AR—smooth muscle tissue—uterine cancer	0.000164	0.00645	CbGeAlD
Danazol—ESR1—smooth muscle tissue—uterine cancer	0.000161	0.00633	CbGeAlD
Danazol—AR—decidua—uterine cancer	0.000161	0.00632	CbGeAlD
Danazol—SHBG—female gonad—uterine cancer	0.00016	0.0063	CbGeAlD
Danazol—SHBG—vagina—uterine cancer	0.000159	0.00627	CbGeAlD
Danazol—CYP19A1—uterus—uterine cancer	0.000159	0.00625	CbGeAlD
Danazol—PGR—female reproductive system—uterine cancer	0.000159	0.00624	CbGeAlD
Danazol—AR—renal system—uterine cancer	0.000158	0.00621	CbGeAlD
Danazol—ESR1—decidua—uterine cancer	0.000158	0.00621	CbGeAlD
Danazol—ESR1—renal system—uterine cancer	0.000155	0.0061	CbGeAlD
Danazol—AR—endometrium—uterine cancer	0.000153	0.006	CbGeAlD
Danazol—ESR1—endometrium—uterine cancer	0.00015	0.00589	CbGeAlD
Danazol—AR—mammalian vulva—uterine cancer	0.000148	0.00581	CbGeAlD
Danazol—PGR—female gonad—uterine cancer	0.000144	0.00568	CbGeAlD
Danazol—PGR—vagina—uterine cancer	0.000144	0.00565	CbGeAlD
Danazol—CYP19A1—female reproductive system—uterine cancer	0.000143	0.00562	CbGeAlD
Danazol—Norelgestromin—PGR—uterine cancer	0.000142	0.086	CrCbGaD
Danazol—Trilostane—ESR2—uterine cancer	0.000142	0.0859	CrCbGaD
Danazol—AR—uterus—uterine cancer	0.000141	0.00553	CbGeAlD
Danazol—ESR1—uterus—uterine cancer	0.000138	0.00543	CbGeAlD
Danazol—Desogestrel—PGR—uterine cancer	0.000137	0.0828	CrCbGaD
Danazol—CYP19A1—female gonad—uterine cancer	0.00013	0.00511	CbGeAlD
Danazol—AR—female reproductive system—uterine cancer	0.000126	0.00497	CbGeAlD
Danazol—ESR1—female reproductive system—uterine cancer	0.000124	0.00488	CbGeAlD
Danazol—Acute coronary syndrome—Medroxyprogesterone Acetate—uterine cancer	0.000123	0.00401	CcSEcCtD
Danazol—Myocardial infarction—Medroxyprogesterone Acetate—uterine cancer	0.000122	0.00399	CcSEcCtD
Danazol—Jaundice—Medroxyprogesterone Acetate—uterine cancer	0.000121	0.00397	CcSEcCtD
Danazol—Sweating—Medroxyprogesterone Acetate—uterine cancer	0.000119	0.0039	CcSEcCtD
Danazol—Visual impairment—Progesterone—uterine cancer	0.000119	0.00388	CcSEcCtD
Danazol—Erythema multiforme—Progesterone—uterine cancer	0.000117	0.00381	CcSEcCtD
Danazol—Pelvic pain—Epirubicin—uterine cancer	0.000116	0.00378	CcSEcCtD
Danazol—Quinestrol—ESR1—uterine cancer	0.000115	0.0698	CrCbGaD
Danazol—AR—female gonad—uterine cancer	0.000115	0.00452	CbGeAlD
Danazol—Gingival bleeding—Doxorubicin—uterine cancer	0.000115	0.00375	CcSEcCtD
Danazol—AR—vagina—uterine cancer	0.000114	0.0045	CbGeAlD
Danazol—ESR1—female gonad—uterine cancer	0.000113	0.00444	CbGeAlD
Danazol—Haemoglobin—Medroxyprogesterone Acetate—uterine cancer	0.000112	0.00367	CcSEcCtD
Danazol—ESR1—vagina—uterine cancer	0.000112	0.00442	CbGeAlD
Danazol—Haemorrhage—Medroxyprogesterone Acetate—uterine cancer	0.000112	0.00365	CcSEcCtD
Danazol—Etonogestrel—PGR—uterine cancer	0.000111	0.067	CrCbGaD
Danazol—Alopecia—Progesterone—uterine cancer	0.000109	0.00356	CcSEcCtD
Danazol—Visual impairment—Medroxyprogesterone Acetate—uterine cancer	0.000108	0.00352	CcSEcCtD
Danazol—Pelvic pain—Doxorubicin—uterine cancer	0.000107	0.0035	CcSEcCtD
Danazol—Erythema multiforme—Medroxyprogesterone Acetate—uterine cancer	0.000106	0.00345	CcSEcCtD
Danazol—Tension—Progesterone—uterine cancer	0.000105	0.00344	CcSEcCtD
Danazol—Nervousness—Progesterone—uterine cancer	0.000104	0.00341	CcSEcCtD
Danazol—Back pain—Progesterone—uterine cancer	0.000104	0.00339	CcSEcCtD
Danazol—Seborrhoeic dermatitis—Epirubicin—uterine cancer	0.000103	0.00338	CcSEcCtD
Danazol—Muscle spasms—Progesterone—uterine cancer	0.000103	0.00337	CcSEcCtD
Danazol—Testolactone—CYP19A1—uterine cancer	0.000102	0.0615	CrCbGaD
Danazol—Vision blurred—Progesterone—uterine cancer	0.000101	0.00331	CcSEcCtD
Danazol—Tremor—Progesterone—uterine cancer	0.000101	0.00329	CcSEcCtD
Danazol—Chills—Medroxyprogesterone Acetate—uterine cancer	0.0001	0.00328	CcSEcCtD
Danazol—Thrombosis—Epirubicin—uterine cancer	9.96e-05	0.00325	CcSEcCtD
Danazol—Alopecia—Medroxyprogesterone Acetate—uterine cancer	9.88e-05	0.00323	CcSEcCtD
Danazol—Vertigo—Progesterone—uterine cancer	9.65e-05	0.00315	CcSEcCtD
Danazol—Syncope—Progesterone—uterine cancer	9.63e-05	0.00315	CcSEcCtD
Danazol—Stevens-Johnson syndrome—Dactinomycin—uterine cancer	9.63e-05	0.00315	CcSEcCtD
Danazol—Seborrhoeic dermatitis—Doxorubicin—uterine cancer	9.57e-05	0.00312	CcSEcCtD
Danazol—Tension—Medroxyprogesterone Acetate—uterine cancer	9.55e-05	0.00312	CcSEcCtD
Danazol—Palpitations—Progesterone—uterine cancer	9.49e-05	0.0031	CcSEcCtD
Danazol—Nervousness—Medroxyprogesterone Acetate—uterine cancer	9.46e-05	0.00309	CcSEcCtD
Danazol—Loss of consciousness—Progesterone—uterine cancer	9.44e-05	0.00308	CcSEcCtD
Danazol—Back pain—Medroxyprogesterone Acetate—uterine cancer	9.42e-05	0.00308	CcSEcCtD
Danazol—Muscle spasms—Medroxyprogesterone Acetate—uterine cancer	9.36e-05	0.00306	CcSEcCtD
Danazol—Convulsion—Progesterone—uterine cancer	9.31e-05	0.00304	CcSEcCtD
Danazol—PGR—lymph node—uterine cancer	9.28e-05	0.00365	CbGeAlD
Danazol—Hypertension—Progesterone—uterine cancer	9.28e-05	0.00303	CcSEcCtD
Danazol—Thrombosis—Doxorubicin—uterine cancer	9.21e-05	0.00301	CcSEcCtD
Danazol—Arthralgia—Progesterone—uterine cancer	9.15e-05	0.00299	CcSEcCtD
Danazol—Tremor—Medroxyprogesterone Acetate—uterine cancer	9.12e-05	0.00298	CcSEcCtD
Danazol—Anxiety—Progesterone—uterine cancer	9.11e-05	0.00298	CcSEcCtD
Danazol—Oedema—Progesterone—uterine cancer	8.77e-05	0.00286	CcSEcCtD
Danazol—Vertigo—Medroxyprogesterone Acetate—uterine cancer	8.75e-05	0.00286	CcSEcCtD
Danazol—Syncope—Medroxyprogesterone Acetate—uterine cancer	8.73e-05	0.00285	CcSEcCtD
Danazol—Mestranol—ESR1—uterine cancer	8.73e-05	0.0529	CrCbGaD
Danazol—Trilostane—ESR1—uterine cancer	8.73e-05	0.0529	CrCbGaD
Danazol—CYP3A4—renal system—uterine cancer	8.65e-05	0.0034	CbGeAlD
Danazol—Shock—Progesterone—uterine cancer	8.63e-05	0.00282	CcSEcCtD
Danazol—Desogestrel—ESR1—uterine cancer	8.62e-05	0.0523	CrCbGaD
Danazol—Palpitations—Medroxyprogesterone Acetate—uterine cancer	8.6e-05	0.00281	CcSEcCtD
Danazol—Dysphonia—Epirubicin—uterine cancer	8.57e-05	0.0028	CcSEcCtD
Danazol—Tachycardia—Progesterone—uterine cancer	8.56e-05	0.0028	CcSEcCtD
Danazol—Loss of consciousness—Medroxyprogesterone Acetate—uterine cancer	8.56e-05	0.00279	CcSEcCtD
Danazol—Hyperhidrosis—Progesterone—uterine cancer	8.48e-05	0.00277	CcSEcCtD
Danazol—Convulsion—Medroxyprogesterone Acetate—uterine cancer	8.43e-05	0.00276	CcSEcCtD
Danazol—CYP19A1—lymph node—uterine cancer	8.35e-05	0.00329	CbGeAlD
Danazol—Arthralgia—Medroxyprogesterone Acetate—uterine cancer	8.29e-05	0.00271	CcSEcCtD
Danazol—Anxiety—Medroxyprogesterone Acetate—uterine cancer	8.26e-05	0.0027	CcSEcCtD
Danazol—Erythema multiforme—Dactinomycin—uterine cancer	8.25e-05	0.00269	CcSEcCtD
Danazol—Cramp muscle—Etoposide—uterine cancer	8.22e-05	0.00268	CcSEcCtD
Danazol—Flushing—Dactinomycin—uterine cancer	8.1e-05	0.00264	CcSEcCtD
Danazol—Amenorrhoea—Epirubicin—uterine cancer	8.02e-05	0.00262	CcSEcCtD
Danazol—Jaundice cholestatic—Epirubicin—uterine cancer	8.02e-05	0.00262	CcSEcCtD
Danazol—Musculoskeletal discomfort—Progesterone—uterine cancer	7.99e-05	0.00261	CcSEcCtD
Danazol—Oedema—Medroxyprogesterone Acetate—uterine cancer	7.95e-05	0.0026	CcSEcCtD
Danazol—Dysphonia—Doxorubicin—uterine cancer	7.93e-05	0.00259	CcSEcCtD
Danazol—Paraesthesia—Progesterone—uterine cancer	7.87e-05	0.00257	CcSEcCtD
Danazol—Chills—Dactinomycin—uterine cancer	7.83e-05	0.00256	CcSEcCtD
Danazol—Levonorgestrel—PGR—uterine cancer	7.82e-05	0.0474	CrCbGaD
Danazol—Shock—Medroxyprogesterone Acetate—uterine cancer	7.82e-05	0.00255	CcSEcCtD
Danazol—Thrombocytopenia—Medroxyprogesterone Acetate—uterine cancer	7.78e-05	0.00254	CcSEcCtD
Danazol—Tachycardia—Medroxyprogesterone Acetate—uterine cancer	7.75e-05	0.00253	CcSEcCtD
Danazol—Dyspepsia—Progesterone—uterine cancer	7.72e-05	0.00252	CcSEcCtD
Danazol—Alopecia—Dactinomycin—uterine cancer	7.71e-05	0.00252	CcSEcCtD
Danazol—Hyperhidrosis—Medroxyprogesterone Acetate—uterine cancer	7.68e-05	0.00251	CcSEcCtD
Danazol—Fatigue—Progesterone—uterine cancer	7.56e-05	0.00247	CcSEcCtD
Danazol—Constipation—Progesterone—uterine cancer	7.5e-05	0.00245	CcSEcCtD
Danazol—Jaundice cholestatic—Doxorubicin—uterine cancer	7.42e-05	0.00242	CcSEcCtD
Danazol—Amenorrhoea—Doxorubicin—uterine cancer	7.42e-05	0.00242	CcSEcCtD
Danazol—AR—lymph node—uterine cancer	7.4e-05	0.00291	CbGeAlD
Danazol—ESR1—lymph node—uterine cancer	7.26e-05	0.00286	CbGeAlD
Danazol—Musculoskeletal discomfort—Medroxyprogesterone Acetate—uterine cancer	7.24e-05	0.00236	CcSEcCtD
Danazol—Paraesthesia—Medroxyprogesterone Acetate—uterine cancer	7.13e-05	0.00233	CcSEcCtD
Danazol—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	6.99e-05	0.00228	CcSEcCtD
Danazol—Etonogestrel—ESR1—uterine cancer	6.98e-05	0.0423	CrCbGaD
Danazol—Stevens-Johnson syndrome—Etoposide—uterine cancer	6.97e-05	0.00228	CcSEcCtD
Danazol—Urticaria—Progesterone—uterine cancer	6.97e-05	0.00228	CcSEcCtD
Danazol—Acute coronary syndrome—Etoposide—uterine cancer	6.93e-05	0.00226	CcSEcCtD
Danazol—Body temperature increased—Progesterone—uterine cancer	6.93e-05	0.00226	CcSEcCtD
Danazol—CYP3A4—female reproductive system—uterine cancer	6.92e-05	0.00272	CbGeAlD
Danazol—Myocardial infarction—Etoposide—uterine cancer	6.89e-05	0.00225	CcSEcCtD
Danazol—Jaundice—Etoposide—uterine cancer	6.86e-05	0.00224	CcSEcCtD
Danazol—Fatigue—Medroxyprogesterone Acetate—uterine cancer	6.85e-05	0.00224	CcSEcCtD
Danazol—Leukopenia—Dactinomycin—uterine cancer	6.8e-05	0.00222	CcSEcCtD
Danazol—Constipation—Medroxyprogesterone Acetate—uterine cancer	6.79e-05	0.00222	CcSEcCtD
Danazol—Ethinyl Estradiol—ESR2—uterine cancer	6.75e-05	0.0409	CrCbGaD
Danazol—Fluid retention—Epirubicin—uterine cancer	6.69e-05	0.00219	CcSEcCtD
Danazol—Norethindrone—PGR—uterine cancer	6.34e-05	0.0384	CrCbGaD
Danazol—Urticaria—Medroxyprogesterone Acetate—uterine cancer	6.31e-05	0.00206	CcSEcCtD
Danazol—Asthenia—Progesterone—uterine cancer	6.29e-05	0.00205	CcSEcCtD
Danazol—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	6.28e-05	0.00205	CcSEcCtD
Danazol—Pruritus—Progesterone—uterine cancer	6.2e-05	0.00203	CcSEcCtD
Danazol—Oedema—Dactinomycin—uterine cancer	6.2e-05	0.00202	CcSEcCtD
Danazol—Fluid retention—Doxorubicin—uterine cancer	6.19e-05	0.00202	CcSEcCtD
Danazol—Thrombocytopenia—Dactinomycin—uterine cancer	6.07e-05	0.00198	CcSEcCtD
Danazol—Erythema multiforme—Etoposide—uterine cancer	5.97e-05	0.00195	CcSEcCtD
Danazol—Flushing—Etoposide—uterine cancer	5.86e-05	0.00191	CcSEcCtD
Danazol—Hepatic function abnormal—Epirubicin—uterine cancer	5.85e-05	0.00191	CcSEcCtD
Danazol—Photosensitivity—Epirubicin—uterine cancer	5.83e-05	0.0019	CcSEcCtD
Danazol—Dizziness—Progesterone—uterine cancer	5.8e-05	0.00189	CcSEcCtD
Danazol—Asthenia—Medroxyprogesterone Acetate—uterine cancer	5.7e-05	0.00186	CcSEcCtD
Danazol—Chills—Etoposide—uterine cancer	5.66e-05	0.00185	CcSEcCtD
Danazol—Musculoskeletal discomfort—Dactinomycin—uterine cancer	5.65e-05	0.00184	CcSEcCtD
Danazol—Pruritus—Medroxyprogesterone Acetate—uterine cancer	5.62e-05	0.00184	CcSEcCtD
Danazol—Alopecia—Etoposide—uterine cancer	5.58e-05	0.00182	CcSEcCtD
Danazol—Vomiting—Progesterone—uterine cancer	5.57e-05	0.00182	CcSEcCtD
Danazol—Rash—Progesterone—uterine cancer	5.53e-05	0.00181	CcSEcCtD
Danazol—Dermatitis—Progesterone—uterine cancer	5.52e-05	0.0018	CcSEcCtD
Danazol—Headache—Progesterone—uterine cancer	5.49e-05	0.00179	CcSEcCtD
Danazol—Hepatic function abnormal—Doxorubicin—uterine cancer	5.42e-05	0.00177	CcSEcCtD
Danazol—Photosensitivity—Doxorubicin—uterine cancer	5.39e-05	0.00176	CcSEcCtD
Danazol—Levonorgestrel—CYP19A1—uterine cancer	5.36e-05	0.0325	CrCbGaD
Danazol—Fatigue—Dactinomycin—uterine cancer	5.34e-05	0.00175	CcSEcCtD
Danazol—Back pain—Etoposide—uterine cancer	5.32e-05	0.00174	CcSEcCtD
Danazol—Muscle spasms—Etoposide—uterine cancer	5.28e-05	0.00173	CcSEcCtD
Danazol—Dizziness—Medroxyprogesterone Acetate—uterine cancer	5.25e-05	0.00172	CcSEcCtD
Danazol—Nausea—Progesterone—uterine cancer	5.21e-05	0.0017	CcSEcCtD
Danazol—Vomiting—Medroxyprogesterone Acetate—uterine cancer	5.05e-05	0.00165	CcSEcCtD
Danazol—Affect lability—Epirubicin—uterine cancer	5.04e-05	0.00164	CcSEcCtD
Danazol—Migraine—Epirubicin—uterine cancer	5.04e-05	0.00164	CcSEcCtD
Danazol—Rash—Medroxyprogesterone Acetate—uterine cancer	5.01e-05	0.00164	CcSEcCtD
Danazol—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	5e-05	0.00163	CcSEcCtD
Danazol—Headache—Medroxyprogesterone Acetate—uterine cancer	4.98e-05	0.00163	CcSEcCtD
Danazol—Vertigo—Etoposide—uterine cancer	4.94e-05	0.00161	CcSEcCtD
Danazol—Levonorgestrel—ESR1—uterine cancer	4.94e-05	0.0299	CrCbGaD
Danazol—Leukopenia—Etoposide—uterine cancer	4.92e-05	0.00161	CcSEcCtD
Danazol—Body temperature increased—Dactinomycin—uterine cancer	4.9e-05	0.0016	CcSEcCtD
Danazol—Mood swings—Epirubicin—uterine cancer	4.85e-05	0.00158	CcSEcCtD
Danazol—Loss of consciousness—Etoposide—uterine cancer	4.83e-05	0.00158	CcSEcCtD
Danazol—Convulsion—Etoposide—uterine cancer	4.76e-05	0.00156	CcSEcCtD
Danazol—Hypertension—Etoposide—uterine cancer	4.74e-05	0.00155	CcSEcCtD
Danazol—Nausea—Medroxyprogesterone Acetate—uterine cancer	4.72e-05	0.00154	CcSEcCtD
Danazol—Fluoxymesterone—ESR1—uterine cancer	4.7e-05	0.0285	CrCbGaD
Danazol—Abdominal pain upper—Epirubicin—uterine cancer	4.67e-05	0.00153	CcSEcCtD
Danazol—Affect lability—Doxorubicin—uterine cancer	4.66e-05	0.00152	CcSEcCtD
Danazol—Migraine—Doxorubicin—uterine cancer	4.66e-05	0.00152	CcSEcCtD
Danazol—Testosterone—CYP11A1—uterine cancer	4.63e-05	0.0281	CrCbGaD
Danazol—Mood swings—Doxorubicin—uterine cancer	4.48e-05	0.00146	CcSEcCtD
Danazol—Asthenia—Dactinomycin—uterine cancer	4.45e-05	0.00145	CcSEcCtD
Danazol—Thrombocytopenia—Etoposide—uterine cancer	4.39e-05	0.00143	CcSEcCtD
Danazol—Tachycardia—Etoposide—uterine cancer	4.38e-05	0.00143	CcSEcCtD
Danazol—Eosinophilia—Epirubicin—uterine cancer	4.38e-05	0.00143	CcSEcCtD
Danazol—Hyperhidrosis—Etoposide—uterine cancer	4.34e-05	0.00142	CcSEcCtD
Danazol—Pancreatitis—Epirubicin—uterine cancer	4.33e-05	0.00142	CcSEcCtD
Danazol—Abdominal pain upper—Doxorubicin—uterine cancer	4.32e-05	0.00141	CcSEcCtD
Danazol—Ethinyl Estradiol—ESR1—uterine cancer	4.16e-05	0.0252	CrCbGaD
Danazol—Methyltestosterone—CYP19A1—uterine cancer	4.13e-05	0.025	CrCbGaD
Danazol—Eosinophilia—Doxorubicin—uterine cancer	4.05e-05	0.00132	CcSEcCtD
Danazol—Photosensitivity reaction—Epirubicin—uterine cancer	4.04e-05	0.00132	CcSEcCtD
Danazol—Paraesthesia—Etoposide—uterine cancer	4.03e-05	0.00132	CcSEcCtD
Danazol—Weight increased—Epirubicin—uterine cancer	4.02e-05	0.00131	CcSEcCtD
Danazol—Pancreatitis—Doxorubicin—uterine cancer	4.01e-05	0.00131	CcSEcCtD
Danazol—Vomiting—Dactinomycin—uterine cancer	3.94e-05	0.00129	CcSEcCtD
Danazol—Stevens-Johnson syndrome—Epirubicin—uterine cancer	3.91e-05	0.00128	CcSEcCtD
Danazol—Rash—Dactinomycin—uterine cancer	3.91e-05	0.00128	CcSEcCtD
Danazol—Fatigue—Etoposide—uterine cancer	3.87e-05	0.00126	CcSEcCtD
Danazol—Jaundice—Epirubicin—uterine cancer	3.84e-05	0.00126	CcSEcCtD
Danazol—Constipation—Etoposide—uterine cancer	3.84e-05	0.00125	CcSEcCtD
Danazol—Sweating—Epirubicin—uterine cancer	3.78e-05	0.00123	CcSEcCtD
Danazol—Haematuria—Epirubicin—uterine cancer	3.76e-05	0.00123	CcSEcCtD
Danazol—Photosensitivity reaction—Doxorubicin—uterine cancer	3.73e-05	0.00122	CcSEcCtD
Danazol—Weight increased—Doxorubicin—uterine cancer	3.72e-05	0.00122	CcSEcCtD
Danazol—Progesterone—PGR—uterine cancer	3.69e-05	0.0224	CrCbGaD
Danazol—Nausea—Dactinomycin—uterine cancer	3.68e-05	0.0012	CcSEcCtD
Danazol—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	3.62e-05	0.00118	CcSEcCtD
Danazol—Urticaria—Etoposide—uterine cancer	3.56e-05	0.00116	CcSEcCtD
Danazol—Haemoglobin—Epirubicin—uterine cancer	3.56e-05	0.00116	CcSEcCtD
Danazol—Jaundice—Doxorubicin—uterine cancer	3.56e-05	0.00116	CcSEcCtD
Danazol—Body temperature increased—Etoposide—uterine cancer	3.55e-05	0.00116	CcSEcCtD
Danazol—Haemorrhage—Epirubicin—uterine cancer	3.54e-05	0.00116	CcSEcCtD
Danazol—Sweating—Doxorubicin—uterine cancer	3.5e-05	0.00114	CcSEcCtD
Danazol—Haematuria—Doxorubicin—uterine cancer	3.48e-05	0.00114	CcSEcCtD
Danazol—Visual impairment—Epirubicin—uterine cancer	3.41e-05	0.00111	CcSEcCtD
Danazol—Erythema multiforme—Epirubicin—uterine cancer	3.35e-05	0.00109	CcSEcCtD
Danazol—Haemoglobin—Doxorubicin—uterine cancer	3.29e-05	0.00107	CcSEcCtD
Danazol—Flushing—Epirubicin—uterine cancer	3.28e-05	0.00107	CcSEcCtD
Danazol—Haemorrhage—Doxorubicin—uterine cancer	3.27e-05	0.00107	CcSEcCtD
Danazol—Asthenia—Etoposide—uterine cancer	3.22e-05	0.00105	CcSEcCtD
Danazol—Chills—Epirubicin—uterine cancer	3.18e-05	0.00104	CcSEcCtD
Danazol—Pruritus—Etoposide—uterine cancer	3.17e-05	0.00104	CcSEcCtD
Danazol—Visual impairment—Doxorubicin—uterine cancer	3.16e-05	0.00103	CcSEcCtD
Danazol—Alopecia—Epirubicin—uterine cancer	3.13e-05	0.00102	CcSEcCtD
Danazol—Erythema multiforme—Doxorubicin—uterine cancer	3.1e-05	0.00101	CcSEcCtD
Danazol—Flushing—Doxorubicin—uterine cancer	3.04e-05	0.000993	CcSEcCtD
Danazol—Tension—Epirubicin—uterine cancer	3.02e-05	0.000987	CcSEcCtD
Danazol—Nervousness—Epirubicin—uterine cancer	2.99e-05	0.000977	CcSEcCtD
Danazol—Back pain—Epirubicin—uterine cancer	2.98e-05	0.000973	CcSEcCtD
Danazol—Dizziness—Etoposide—uterine cancer	2.97e-05	0.000969	CcSEcCtD
Danazol—Muscle spasms—Epirubicin—uterine cancer	2.96e-05	0.000967	CcSEcCtD
Danazol—Chills—Doxorubicin—uterine cancer	2.94e-05	0.00096	CcSEcCtD
Danazol—Vision blurred—Epirubicin—uterine cancer	2.9e-05	0.000948	CcSEcCtD
Danazol—Alopecia—Doxorubicin—uterine cancer	2.89e-05	0.000945	CcSEcCtD
Danazol—Vomiting—Etoposide—uterine cancer	2.85e-05	0.000932	CcSEcCtD
Danazol—Rash—Etoposide—uterine cancer	2.83e-05	0.000924	CcSEcCtD
Danazol—Dermatitis—Etoposide—uterine cancer	2.83e-05	0.000923	CcSEcCtD
Danazol—Headache—Etoposide—uterine cancer	2.81e-05	0.000918	CcSEcCtD
Danazol—Tension—Doxorubicin—uterine cancer	2.8e-05	0.000914	CcSEcCtD
Danazol—Nervousness—Doxorubicin—uterine cancer	2.77e-05	0.000904	CcSEcCtD
Danazol—Vertigo—Epirubicin—uterine cancer	2.77e-05	0.000904	CcSEcCtD
Danazol—Syncope—Epirubicin—uterine cancer	2.76e-05	0.000902	CcSEcCtD
Danazol—Leukopenia—Epirubicin—uterine cancer	2.76e-05	0.000901	CcSEcCtD
Danazol—Back pain—Doxorubicin—uterine cancer	2.76e-05	0.000901	CcSEcCtD
Danazol—Muscle spasms—Doxorubicin—uterine cancer	2.74e-05	0.000895	CcSEcCtD
Danazol—Palpitations—Epirubicin—uterine cancer	2.72e-05	0.000889	CcSEcCtD
Danazol—Loss of consciousness—Epirubicin—uterine cancer	2.71e-05	0.000884	CcSEcCtD
Danazol—Vision blurred—Doxorubicin—uterine cancer	2.69e-05	0.000877	CcSEcCtD
Danazol—Convulsion—Epirubicin—uterine cancer	2.67e-05	0.000872	CcSEcCtD
Danazol—Nausea—Etoposide—uterine cancer	2.66e-05	0.00087	CcSEcCtD
Danazol—Hypertension—Epirubicin—uterine cancer	2.66e-05	0.000869	CcSEcCtD
Danazol—Arthralgia—Epirubicin—uterine cancer	2.62e-05	0.000857	CcSEcCtD
Danazol—Anxiety—Epirubicin—uterine cancer	2.61e-05	0.000854	CcSEcCtD
Danazol—Vertigo—Doxorubicin—uterine cancer	2.56e-05	0.000837	CcSEcCtD
Danazol—Syncope—Doxorubicin—uterine cancer	2.56e-05	0.000835	CcSEcCtD
Danazol—Leukopenia—Doxorubicin—uterine cancer	2.55e-05	0.000833	CcSEcCtD
Danazol—Palpitations—Doxorubicin—uterine cancer	2.52e-05	0.000823	CcSEcCtD
Danazol—Oedema—Epirubicin—uterine cancer	2.51e-05	0.000821	CcSEcCtD
Danazol—Loss of consciousness—Doxorubicin—uterine cancer	2.51e-05	0.000818	CcSEcCtD
Danazol—Shock—Epirubicin—uterine cancer	2.47e-05	0.000808	CcSEcCtD
Danazol—Convulsion—Doxorubicin—uterine cancer	2.47e-05	0.000807	CcSEcCtD
Danazol—Thrombocytopenia—Epirubicin—uterine cancer	2.46e-05	0.000804	CcSEcCtD
Danazol—Hypertension—Doxorubicin—uterine cancer	2.46e-05	0.000804	CcSEcCtD
Danazol—Tachycardia—Epirubicin—uterine cancer	2.45e-05	0.000802	CcSEcCtD
Danazol—Hyperhidrosis—Epirubicin—uterine cancer	2.43e-05	0.000794	CcSEcCtD
Danazol—Arthralgia—Doxorubicin—uterine cancer	2.43e-05	0.000793	CcSEcCtD
Danazol—Anxiety—Doxorubicin—uterine cancer	2.42e-05	0.00079	CcSEcCtD
Danazol—Testosterone—CYP19A1—uterine cancer	2.39e-05	0.0145	CrCbGaD
Danazol—Progesterone—ESR1—uterine cancer	2.33e-05	0.0141	CrCbGaD
Danazol—Oedema—Doxorubicin—uterine cancer	2.33e-05	0.00076	CcSEcCtD
Danazol—Musculoskeletal discomfort—Epirubicin—uterine cancer	2.29e-05	0.000748	CcSEcCtD
Danazol—Shock—Doxorubicin—uterine cancer	2.29e-05	0.000748	CcSEcCtD
Danazol—Thrombocytopenia—Doxorubicin—uterine cancer	2.28e-05	0.000744	CcSEcCtD
Danazol—Tachycardia—Doxorubicin—uterine cancer	2.27e-05	0.000742	CcSEcCtD
Danazol—Paraesthesia—Epirubicin—uterine cancer	2.26e-05	0.000737	CcSEcCtD
Danazol—Hyperhidrosis—Doxorubicin—uterine cancer	2.25e-05	0.000735	CcSEcCtD
Danazol—Dyspepsia—Epirubicin—uterine cancer	2.21e-05	0.000723	CcSEcCtD
Danazol—Fatigue—Epirubicin—uterine cancer	2.17e-05	0.000708	CcSEcCtD
Danazol—Constipation—Epirubicin—uterine cancer	2.15e-05	0.000702	CcSEcCtD
Danazol—Musculoskeletal discomfort—Doxorubicin—uterine cancer	2.12e-05	0.000692	CcSEcCtD
Danazol—Paraesthesia—Doxorubicin—uterine cancer	2.09e-05	0.000682	CcSEcCtD
Danazol—Dyspepsia—Doxorubicin—uterine cancer	2.05e-05	0.000669	CcSEcCtD
Danazol—Fatigue—Doxorubicin—uterine cancer	2.01e-05	0.000655	CcSEcCtD
Danazol—Urticaria—Epirubicin—uterine cancer	2e-05	0.000652	CcSEcCtD
Danazol—Constipation—Doxorubicin—uterine cancer	1.99e-05	0.00065	CcSEcCtD
Danazol—Body temperature increased—Epirubicin—uterine cancer	1.99e-05	0.000649	CcSEcCtD
Danazol—Urticaria—Doxorubicin—uterine cancer	1.85e-05	0.000604	CcSEcCtD
Danazol—Body temperature increased—Doxorubicin—uterine cancer	1.84e-05	0.000601	CcSEcCtD
Danazol—Asthenia—Epirubicin—uterine cancer	1.8e-05	0.000589	CcSEcCtD
Danazol—Pruritus—Epirubicin—uterine cancer	1.78e-05	0.000581	CcSEcCtD
Danazol—Asthenia—Doxorubicin—uterine cancer	1.67e-05	0.000545	CcSEcCtD
Danazol—Dizziness—Epirubicin—uterine cancer	1.66e-05	0.000543	CcSEcCtD
Danazol—Pruritus—Doxorubicin—uterine cancer	1.65e-05	0.000538	CcSEcCtD
Danazol—Vomiting—Epirubicin—uterine cancer	1.6e-05	0.000522	CcSEcCtD
Danazol—Rash—Epirubicin—uterine cancer	1.59e-05	0.000518	CcSEcCtD
Danazol—Dermatitis—Epirubicin—uterine cancer	1.58e-05	0.000517	CcSEcCtD
Danazol—Headache—Epirubicin—uterine cancer	1.58e-05	0.000514	CcSEcCtD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	1.57e-05	0.000818	CbGpPWpGaD
Danazol—AR—Integrated Breast Cancer Pathway—EP300—uterine cancer	1.54e-05	0.000806	CbGpPWpGaD
Danazol—Dizziness—Doxorubicin—uterine cancer	1.54e-05	0.000502	CcSEcCtD
Danazol—ESR1—Generic Transcription Pathway—PGR—uterine cancer	1.53e-05	0.000802	CbGpPWpGaD
Danazol—AR—Regulation of nuclear SMAD2/3 signaling—AKT1—uterine cancer	1.53e-05	0.000802	CbGpPWpGaD
Danazol—AR—SIDS Susceptibility Pathways—EP300—uterine cancer	1.5e-05	0.000785	CbGpPWpGaD
Danazol—Nausea—Epirubicin—uterine cancer	1.49e-05	0.000488	CcSEcCtD
Danazol—PGR—Signaling by ERBB4—PIK3CA—uterine cancer	1.49e-05	0.000778	CbGpPWpGaD
Danazol—ESR1—Gene Expression—SUZ12—uterine cancer	1.48e-05	0.000775	CbGpPWpGaD
Danazol—Vomiting—Doxorubicin—uterine cancer	1.48e-05	0.000483	CcSEcCtD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	1.48e-05	0.000773	CbGpPWpGaD
Danazol—Rash—Doxorubicin—uterine cancer	1.47e-05	0.000479	CcSEcCtD
Danazol—Dermatitis—Doxorubicin—uterine cancer	1.47e-05	0.000479	CcSEcCtD
Danazol—AR—Integrated Breast Cancer Pathway—VEGFA—uterine cancer	1.46e-05	0.000763	CbGpPWpGaD
Danazol—Headache—Doxorubicin—uterine cancer	1.46e-05	0.000476	CcSEcCtD
Danazol—CCL2—Signaling Pathways—AKR1C3—uterine cancer	1.46e-05	0.000761	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	1.46e-05	0.00076	CbGpPWpGaD
Danazol—ESR1—Signaling by ERBB4—ERBB2—uterine cancer	1.45e-05	0.000759	CbGpPWpGaD
Danazol—CYP3A4—Metapathway biotransformation—AKR1C1—uterine cancer	1.44e-05	0.000752	CbGpPWpGaD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—CTNNB1—uterine cancer	1.43e-05	0.000746	CbGpPWpGaD
Danazol—AR—Generic Transcription Pathway—CDKN2B—uterine cancer	1.43e-05	0.000746	CbGpPWpGaD
Danazol—ESR1—Leptin signaling pathway—HRAS—uterine cancer	1.42e-05	0.000744	CbGpPWpGaD
Danazol—AR—SIDS Susceptibility Pathways—VEGFA—uterine cancer	1.42e-05	0.000744	CbGpPWpGaD
Danazol—AR—Androgen receptor signaling pathway—AKT1—uterine cancer	1.42e-05	0.000743	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—PGR—uterine cancer	1.42e-05	0.000741	CbGpPWpGaD
Danazol—PGR—Generic Transcription Pathway—ESR1—uterine cancer	1.4e-05	0.000729	CbGpPWpGaD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—PTEN—uterine cancer	1.39e-05	0.000727	CbGpPWpGaD
Danazol—Nausea—Doxorubicin—uterine cancer	1.38e-05	0.000451	CcSEcCtD
Danazol—PGR—Signaling by ERBB4—HRAS—uterine cancer	1.38e-05	0.00072	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	1.37e-05	0.000718	CbGpPWpGaD
Danazol—ESR1—Regulation of Telomerase—AKT1—uterine cancer	1.36e-05	0.00071	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—YWHAE—uterine cancer	1.35e-05	0.000707	CbGpPWpGaD
Danazol—ESR1—Generic Transcription Pathway—ESR2—uterine cancer	1.35e-05	0.000706	CbGpPWpGaD
Danazol—ESR1—Signaling by ERBB4—CDKN1B—uterine cancer	1.35e-05	0.000703	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	1.34e-05	0.0007	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—AKR1C3—uterine cancer	1.33e-05	0.000696	CbGpPWpGaD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—EP300—uterine cancer	1.33e-05	0.000693	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—RNF43—uterine cancer	1.32e-05	0.000692	CbGpPWpGaD
Danazol—AR—Generic Transcription Pathway—SMAD3—uterine cancer	1.3e-05	0.000681	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—FBXW7—uterine cancer	1.3e-05	0.000678	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—PGR—uterine cancer	1.3e-05	0.000678	CbGpPWpGaD
Danazol—ESR1—Integrated Breast Cancer Pathway—CTNNB1—uterine cancer	1.28e-05	0.000668	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	1.28e-05	0.000668	CbGpPWpGaD
Danazol—CYP3A4—Metapathway biotransformation—GPX3—uterine cancer	1.26e-05	0.00066	CbGpPWpGaD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—VEGFA—uterine cancer	1.26e-05	0.000657	CbGpPWpGaD
Danazol—ESR1—Leptin signaling pathway—AKT1—uterine cancer	1.26e-05	0.000657	CbGpPWpGaD
Danazol—ESR1—Integrated Breast Cancer Pathway—PTEN—uterine cancer	1.25e-05	0.000651	CbGpPWpGaD
Danazol—AR—Integrated Breast Cancer Pathway—KRAS—uterine cancer	1.24e-05	0.000649	CbGpPWpGaD
Danazol—ESR1—Signaling by ERBB4—PTEN—uterine cancer	1.24e-05	0.000648	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—YWHAE—uterine cancer	1.24e-05	0.000647	CbGpPWpGaD
Danazol—CCL2—Metabolism of proteins—CXCL8—uterine cancer	1.22e-05	0.000639	CbGpPWpGaD
Danazol—PGR—Signaling by ERBB4—AKT1—uterine cancer	1.22e-05	0.000636	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—INHBA—uterine cancer	1.21e-05	0.000633	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	1.21e-05	0.000633	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	1.21e-05	0.000632	CbGpPWpGaD
Danazol—PGR—Gene Expression—EZH2—uterine cancer	1.2e-05	0.000625	CbGpPWpGaD
Danazol—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	1.19e-05	0.000622	CbGpPWpGaD
Danazol—ESR1—Integrated Breast Cancer Pathway—EP300—uterine cancer	1.19e-05	0.000621	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—FBXW7—uterine cancer	1.19e-05	0.00062	CbGpPWpGaD
Danazol—ESR1—Regulation of nuclear SMAD2/3 signaling—AKT1—uterine cancer	1.18e-05	0.000617	CbGpPWpGaD
Danazol—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	1.17e-05	0.000613	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—AKR1B1—uterine cancer	1.17e-05	0.000609	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—STAR—uterine cancer	1.17e-05	0.000609	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—STK11—uterine cancer	1.13e-05	0.000593	CbGpPWpGaD
Danazol—CCL2—Metabolism of proteins—CTNNB1—uterine cancer	1.13e-05	0.00059	CbGpPWpGaD
Danazol—ESR1—Integrated Breast Cancer Pathway—VEGFA—uterine cancer	1.13e-05	0.000588	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	1.12e-05	0.000586	CbGpPWpGaD
Danazol—PGR—Gene Expression—ESR2—uterine cancer	1.11e-05	0.000579	CbGpPWpGaD
Danazol—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	1.11e-05	0.000579	CbGpPWpGaD
Danazol—ESR1—Signaling by ERBB4—NRAS—uterine cancer	1.11e-05	0.000578	CbGpPWpGaD
Danazol—AR—Integrated Breast Cancer Pathway—TP53—uterine cancer	1.1e-05	0.000577	CbGpPWpGaD
Danazol—ESR1—Generic Transcription Pathway—CDKN2B—uterine cancer	1.1e-05	0.000575	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—AKR1C1—uterine cancer	1.09e-05	0.00057	CbGpPWpGaD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—KRAS—uterine cancer	1.07e-05	0.000558	CbGpPWpGaD
Danazol—AR—Generic Transcription Pathway—ESR1—uterine cancer	1.06e-05	0.000556	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—SOCS3—uterine cancer	1.06e-05	0.000555	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	1.06e-05	0.000553	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—STK11—uterine cancer	1.04e-05	0.000542	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—CCL2—uterine cancer	1.03e-05	0.00054	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	1.03e-05	0.000539	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	1.03e-05	0.000538	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—CDKN2B—uterine cancer	1.02e-05	0.000531	CbGpPWpGaD
Danazol—ESR1—Generic Transcription Pathway—SMAD3—uterine cancer	1e-05	0.000525	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—IGF1R—uterine cancer	9.87e-06	0.000516	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	9.84e-06	0.000514	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—SOCS3—uterine cancer	9.71e-06	0.000508	CbGpPWpGaD
Danazol—AR—Gene Expression—PGR—uterine cancer	9.59e-06	0.000501	CbGpPWpGaD
Danazol—ESR1—Integrated Breast Cancer Pathway—KRAS—uterine cancer	9.56e-06	0.0005	CbGpPWpGaD
Danazol—ESR1—Signaling by ERBB4—KRAS—uterine cancer	9.51e-06	0.000497	CbGpPWpGaD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—TP53—uterine cancer	9.5e-06	0.000496	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	9.45e-06	0.000494	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—AKR1B10—uterine cancer	9.38e-06	0.00049	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	9.32e-06	0.000487	CbGpPWpGaD
Danazol—AR—Integrated Breast Cancer Pathway—AKT1—uterine cancer	9.32e-06	0.000487	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—CDKN2B—uterine cancer	9.3e-06	0.000486	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—SMAD3—uterine cancer	9.28e-06	0.000485	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	9.14e-06	0.000478	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—POLD1—uterine cancer	9.14e-06	0.000478	CbGpPWpGaD
Danazol—AR—Gene Expression—EZH2—uterine cancer	9.11e-06	0.000476	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—IGF1R—uterine cancer	9.03e-06	0.000472	CbGpPWpGaD
Danazol—PGR—Gene Expression—CDKN2B—uterine cancer	9.02e-06	0.000471	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—CXCL8—uterine cancer	8.99e-06	0.00047	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—CXCL8—uterine cancer	8.93e-06	0.000466	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—FGFR2—uterine cancer	8.85e-06	0.000463	CbGpPWpGaD
Danazol—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	8.75e-06	0.000457	CbGpPWpGaD
Danazol—ESR1—Signaling by ERBB4—PIK3CA—uterine cancer	8.74e-06	0.000457	CbGpPWpGaD
Danazol—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	8.63e-06	0.000451	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—AKR1C1—uterine cancer	8.55e-06	0.000447	CbGpPWpGaD
Danazol—ESR1—Integrated Breast Cancer Pathway—TP53—uterine cancer	8.5e-06	0.000444	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—SMAD3—uterine cancer	8.49e-06	0.000444	CbGpPWpGaD
Danazol—AR—Gene Expression—ESR2—uterine cancer	8.44e-06	0.000441	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—AKR1C3—uterine cancer	8.4e-06	0.000439	CbGpPWpGaD
Danazol—PGR—Gene Expression—SMAD3—uterine cancer	8.23e-06	0.00043	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—CXCL8—uterine cancer	8.16e-06	0.000427	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—FGFR2—uterine cancer	8.1e-06	0.000423	CbGpPWpGaD
Danazol—ESR1—Signaling by ERBB4—HRAS—uterine cancer	8.09e-06	0.000423	CbGpPWpGaD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—AKT1—uterine cancer	8.02e-06	0.000419	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	7.93e-06	0.000414	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—YWHAE—uterine cancer	7.81e-06	0.000408	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—RNF43—uterine cancer	7.77e-06	0.000406	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	7.72e-06	0.000404	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—RRM2—uterine cancer	7.62e-06	0.000398	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—ESR1—uterine cancer	7.58e-06	0.000396	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—FBXW7—uterine cancer	7.48e-06	0.000391	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—DCN—uterine cancer	7.4e-06	0.000387	CbGpPWpGaD
Danazol—ESR1—Gene Expression—PGR—uterine cancer	7.39e-06	0.000386	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	7.28e-06	0.000381	CbGpPWpGaD
Danazol—ESR1—Integrated Breast Cancer Pathway—AKT1—uterine cancer	7.18e-06	0.000375	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—NRAS—uterine cancer	7.16e-06	0.000374	CbGpPWpGaD
Danazol—ESR1—Signaling by ERBB4—AKT1—uterine cancer	7.14e-06	0.000373	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—INHBA—uterine cancer	7.11e-06	0.000372	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	7.04e-06	0.000368	CbGpPWpGaD
Danazol—ESR1—Gene Expression—EZH2—uterine cancer	7.02e-06	0.000367	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—CYP11A1—uterine cancer	6.97e-06	0.000364	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—ESR1—uterine cancer	6.93e-06	0.000362	CbGpPWpGaD
Danazol—AR—Gene Expression—CDKN2B—uterine cancer	6.87e-06	0.000359	CbGpPWpGaD
Danazol—PGR—Gene Expression—ESR1—uterine cancer	6.72e-06	0.000351	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—AKR1C3—uterine cancer	6.58e-06	0.000344	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—NRAS—uterine cancer	6.55e-06	0.000342	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—STK11—uterine cancer	6.54e-06	0.000342	CbGpPWpGaD
Danazol—ESR1—Gene Expression—ESR2—uterine cancer	6.5e-06	0.00034	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—AKR1C1—uterine cancer	6.4e-06	0.000335	CbGpPWpGaD
Danazol—AR—Gene Expression—SMAD3—uterine cancer	6.27e-06	0.000328	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—KRAS—uterine cancer	6.16e-06	0.000322	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—SOCS3—uterine cancer	6.13e-06	0.00032	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—CCL2—uterine cancer	6.1e-06	0.000319	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	5.95e-06	0.000311	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—CDKN2B—uterine cancer	5.86e-06	0.000306	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—PIK3CA—uterine cancer	5.7e-06	0.000298	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—IGF1R—uterine cancer	5.69e-06	0.000298	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—PIK3CA—uterine cancer	5.66e-06	0.000296	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—KRAS—uterine cancer	5.64e-06	0.000295	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—ERBB2—uterine cancer	5.56e-06	0.000291	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—SMAD3—uterine cancer	5.35e-06	0.00028	CbGpPWpGaD
Danazol—ESR1—Gene Expression—CDKN2B—uterine cancer	5.29e-06	0.000277	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—CXCL8—uterine cancer	5.27e-06	0.000276	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—HRAS—uterine cancer	5.24e-06	0.000274	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—PIK3CA—uterine cancer	5.18e-06	0.000271	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—CDKN1B—uterine cancer	5.15e-06	0.000269	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—STK11—uterine cancer	5.13e-06	0.000268	CbGpPWpGaD
Danazol—AR—Gene Expression—ESR1—uterine cancer	5.12e-06	0.000268	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—FGFR2—uterine cancer	5.11e-06	0.000267	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—ERBB2—uterine cancer	5.09e-06	0.000266	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—AKR1C3—uterine cancer	4.93e-06	0.000258	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—CTNNB1—uterine cancer	4.86e-06	0.000254	CbGpPWpGaD
Danazol—ESR1—Gene Expression—SMAD3—uterine cancer	4.83e-06	0.000253	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—CXCL8—uterine cancer	4.82e-06	0.000252	CbGpPWpGaD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	4.81e-06	0.000252	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—PGR—uterine cancer	4.8e-06	0.000251	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—HRAS—uterine cancer	4.79e-06	0.00025	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—PTEN—uterine cancer	4.74e-06	0.000248	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—CDKN1B—uterine cancer	4.71e-06	0.000246	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—NDUFB11—uterine cancer	4.7e-06	0.000246	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—SRD5A2—uterine cancer	4.7e-06	0.000246	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—AKT1—uterine cancer	4.66e-06	0.000243	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—AKT1—uterine cancer	4.63e-06	0.000242	CbGpPWpGaD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	4.59e-06	0.00024	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—YWHAE—uterine cancer	4.58e-06	0.000239	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—EP300—uterine cancer	4.52e-06	0.000236	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—CTNNB1—uterine cancer	4.45e-06	0.000233	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—FBXW7—uterine cancer	4.39e-06	0.00023	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—ESR1—uterine cancer	4.37e-06	0.000228	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—PTEN—uterine cancer	4.34e-06	0.000227	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—VEGFA—uterine cancer	4.28e-06	0.000224	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—AKT1—uterine cancer	4.23e-06	0.000221	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—NRAS—uterine cancer	4.23e-06	0.000221	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—EP300—uterine cancer	4.14e-06	0.000216	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—VEGFA—uterine cancer	3.92e-06	0.000205	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—NRAS—uterine cancer	3.87e-06	0.000202	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—MTHFR—uterine cancer	3.85e-06	0.000201	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—CCL2—uterine cancer	3.85e-06	0.000201	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—STK11—uterine cancer	3.84e-06	0.000201	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—KRAS—uterine cancer	3.64e-06	0.00019	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—SOCS3—uterine cancer	3.59e-06	0.000188	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—CDKN2B—uterine cancer	3.44e-06	0.00018	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—AKR1B1—uterine cancer	3.4e-06	0.000178	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—STAR—uterine cancer	3.4e-06	0.000178	CbGpPWpGaD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.4e-06	0.000177	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—PIK3CA—uterine cancer	3.34e-06	0.000175	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—IGF1R—uterine cancer	3.34e-06	0.000175	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—KRAS—uterine cancer	3.33e-06	0.000174	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—TP53—uterine cancer	3.24e-06	0.000169	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—ERBB2—uterine cancer	3.21e-06	0.000168	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—SMAD3—uterine cancer	3.14e-06	0.000164	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—HRAS—uterine cancer	3.09e-06	0.000162	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—PIK3CA—uterine cancer	3.06e-06	0.00016	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—CXCL8—uterine cancer	3.04e-06	0.000159	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—FGFR2—uterine cancer	3e-06	0.000157	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—CDKN1B—uterine cancer	2.97e-06	0.000155	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—TP53—uterine cancer	2.96e-06	0.000155	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—HRAS—uterine cancer	2.83e-06	0.000148	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—CTNNB1—uterine cancer	2.81e-06	0.000147	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—PTEN—uterine cancer	2.73e-06	0.000143	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—AKT1—uterine cancer	2.73e-06	0.000143	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—POLD1—uterine cancer	2.67e-06	0.000139	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—EP300—uterine cancer	2.61e-06	0.000136	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—AKT1—uterine cancer	2.5e-06	0.000131	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—AKR1C1—uterine cancer	2.5e-06	0.00013	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—VEGFA—uterine cancer	2.47e-06	0.000129	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—NRAS—uterine cancer	2.44e-06	0.000128	CbGpPWpGaD
Danazol—PGR—Gene Expression—AKT1—uterine cancer	2.42e-06	0.000127	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—CCL2—uterine cancer	2.26e-06	0.000118	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—RRM2—uterine cancer	2.22e-06	0.000116	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—DCN—uterine cancer	2.16e-06	0.000113	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—PTEN—uterine cancer	2.14e-06	0.000112	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—KRAS—uterine cancer	2.1e-06	0.00011	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—EP300—uterine cancer	2.04e-06	0.000107	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—CYP11A1—uterine cancer	2.03e-06	0.000106	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—PIK3CA—uterine cancer	1.93e-06	0.000101	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—AKR1C3—uterine cancer	1.92e-06	0.0001	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—ERBB2—uterine cancer	1.88e-06	9.84e-05	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—TP53—uterine cancer	1.87e-06	9.75e-05	CbGpPWpGaD
Danazol—AR—Gene Expression—AKT1—uterine cancer	1.85e-06	9.65e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—CXCL8—uterine cancer	1.78e-06	9.33e-05	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—HRAS—uterine cancer	1.78e-06	9.33e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—CDKN1B—uterine cancer	1.74e-06	9.11e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—CTNNB1—uterine cancer	1.65e-06	8.61e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—PTEN—uterine cancer	1.6e-06	8.39e-05	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—AKT1—uterine cancer	1.58e-06	8.24e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—EP300—uterine cancer	1.53e-06	8e-05	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—PIK3CA—uterine cancer	1.51e-06	7.9e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—CYP19A1—uterine cancer	1.5e-06	7.82e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—STK11—uterine cancer	1.5e-06	7.82e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—VEGFA—uterine cancer	1.45e-06	7.58e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—NRAS—uterine cancer	1.43e-06	7.48e-05	CbGpPWpGaD
Danazol—ESR1—Gene Expression—AKT1—uterine cancer	1.42e-06	7.43e-05	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—AKT1—uterine cancer	1.24e-06	6.46e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—KRAS—uterine cancer	1.23e-06	6.44e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—PIK3CA—uterine cancer	1.13e-06	5.92e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—MTHFR—uterine cancer	1.12e-06	5.88e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—TP53—uterine cancer	1.1e-06	5.72e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—HRAS—uterine cancer	1.05e-06	5.47e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—AKT1—uterine cancer	9.25e-07	4.83e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—PTEN—uterine cancer	6.26e-07	3.27e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—EP300—uterine cancer	5.97e-07	3.12e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—PIK3CA—uterine cancer	4.41e-07	2.31e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—AKT1—uterine cancer	3.61e-07	1.88e-05	CbGpPWpGaD
